Mary Elmquist
Gerontology · Amarillo, TXNPI 1770766453
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,175 of the $4,787 with a category attached, or 87.2%. It is spread thinly across 36 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,583, 6.3 times the $408 reported in 2021. Among gerontology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$612
- Viiv Healthcare Company$541
- AbbVie$516
- Abbott$398
- Eisai Inc.$393
- Gilead$237
- plus $2K from 30 others
What the payments were for
- Travel & lodging$61213%
- Food & beverage$4,17587%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $612 |
| Viiv Healthcare Company | 21 | $541 |
| AbbVie | 24 | $516 |
| Abbott | 23 | $398 |
| Eisai Inc. | 14 | $393 |
| Gilead | 3 | $237 |
| Lilly USA, LLC | 5 | $227 |
| UCB, Inc. | 7 | $174 |
| Merck | 11 | $167 |
| Mylan Specialty L.p. | 10 | $151 |
| Melinta Therapeutics, LLC | 7 | $138 |
| Ferring Pharmaceuticals Inc. | 1 | $125 |
| EMD Serono, Inc. | 1 | $125 |
| Exact Sciences | 6 | $111 |
| Astellas Pharma US Inc | 6 | $103 |
| Pfizer | 5 | $90 |
| AstraZeneca | 3 | $67 |
| Boehringer Ingelheim | 3 | $61 |
| Bayer | 3 | $57 |
| Lundbeck LLC | 2 | $49 |
| Biogen | 2 | $49 |
| Merz Pharmaceuticals, LLC | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Insmed, Inc. | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Argenx US, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $18 |
| Amgen | 1 | $16 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,787 in reported general payments places this provider in the 90th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 112 | $471,719 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 34 | $138,213 |
| JulucaDolutegravir/Rilpivirine | 32 | $114,344 |
| DescovyEmtricitabine/Tenofov Alafenam | 25 | $54,225 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 14 | $53,637 |
| SelzentryMaraviroc | 13 | $44,720 |
| PrezcobixDarunavir/Cobicistat | 14 | $34,479 |
| TivicayDolutegravir Sodium | 12 | $26,538 |
| IsentressRaltegravir Potassium | 13 | $18,950 |
| Daptomycin | 13 | $16,605 |
| CefuroximeCefuroxime Axetil | 279 | $15,512 |
| Meropenem | 21 | $11,581 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 15 | $8,323 |
| ZiagenAbacavir Sulfate | 12 | $6,876 |
| Minocycline Hcl | 268 | $5,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Stribild | $237 | $717,794185 claims |
| Viiv Healthcare CompanyJuluca, Tivicay | $541 | $140,88244 claims |
| PfizerSelzentry | $90 | $44,72013 claims |
| MerckIsentress | $167 | $18,95013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 gerontology providers in Texas.
Other gerontology in Amarillo
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Bailey EstesAbilene$34K
- Scott ZelaHouston$28K
- Marissa Marti-SmithDallas$27K
- Andrew BargerAustin$22K
- Meagan ChavarriaHouston$21K
- Samantha BoggsGalveston$15K
- Amber ArmstrongAustin$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.